Biognosys at ENA 2020 - Biognosys

Biognosys at ENA 2020

BIOGNOSYS POSTERS

High-Resolution Limited Proteolysis (HR-LIP): A Novel Approach for Target Validation and Lead Compound Optimization

Y. Feng1, N. Beaton1, J. Adhikari2, R. Bruderer1, R. Tomlinson2, I. Cornella-Taracido2, L. Reiter1.

1) Biognosys AG, Schlieren, Switzerland.
2) Cedilla Therapeutics, Cambridge, USA.

 

Abstract

LiP-Quant, an Automated Chemoproteomic Approach to Identify Drug Targets in Complex Proteomes

Y. Feng1, N. Beaton1, I. Piazza2, R. Bruderer1, P. Picotti2, L. Reiter1.

1) Biognosys, Schlieren, Switzerland.
2) ETH Zurich, Institute of Molecular Systems Biology, Zurich, Switzerland.

 

 

Abstract

MORE INFORMATION

 

More information about our Limited Proteolysis (LiP) technology is available

 

Here

Helpdesk

Access our knowledge base with relevant resources and guiding information.

Contact

    Close banner

    Spectronaut® 16

    The Deepest Proteome
    Coverage Available

    New: Spectronaut® 16

    The Deepest Proteome Coverage Available

    learn more